The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

In a session titled, Better meeting the needs of people living with HIV, health experts reminded us that science, care, and human rights must move together if we are to achieve real change.

These companies have compelling long-term futures, but the coming decade could prove particularly exciting as each one comes into its own.

Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood ...

Researchers have developed a powerful new tool that makes it easier to study the mix of cell types in human tissue, which is ...

European Medicines Agency Supports Streamlined Development Pathway for GEO-MVA Vaccine Candidate via a Single Phase 3 Immuno-bridging Trial ATLANTA, GA - July 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, ...

Fragile X disorders include two distinct conditions: fragile X syndrome (the most common single-gene cause of developmental delay and autism) and an entirely separate group of premutation syndromes.

CMS has reached agreements with drug manufacturers to provide gene therapies to treat sickle cell disease to Medicaid recipients under a new outcomes-based model. A total of 33 states, including the ...

Boehringer Ingelheim Stiftung announces the winner of the 2025 Heinrich Wieland Prize: Adrian R. Krainer of Cold Spring ...